Compare LUNG & POM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | POM |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 47.1M |
| IPO Year | 2020 | N/A |
| Metric | LUNG | POM |
|---|---|---|
| Price | $1.27 | $0.39 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $5.38 | N/A |
| AVG Volume (30 Days) | 298.4K | ★ 1.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,497,000.00 | N/A |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $18.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.01 | N/A |
| 52 Week Low | $1.13 | $0.19 |
| 52 Week High | $5.46 | $6.43 |
| Indicator | LUNG | POM |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 62.84 |
| Support Level | $1.13 | $0.21 |
| Resistance Level | $1.64 | $0.43 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 10.79 | 82.58 |
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.